Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. (Q41519470)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Nico Callewaert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ana Rosa Perez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Iván Alejandro Bontempi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Gabriel Cabrera

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Silvina Raquel Villar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Florencia Belén González

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Eduardo Angel Roggero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Paul Ameloot

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Iván Sergio Marcipar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

25 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1274-1283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25625671%20AND%20SRC:MED&resulttype=core&format=json

Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Genomic analyses, gene expression and antigenic profile of the trans-sialidase superfamily of Trypanosoma cruzi reveal an undetected level of complexity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Vaccine development against Trypanosoma cruzi and Chagas disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Trypanosome trans-sialidase targets TrkA tyrosine kinase receptor and induces receptor internalization and activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

A sexual dimorphism in intrathymic sialylation survey is revealed by the trans-sialidase from Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

7 January 2021

ISCOMs and ISCOMATRIX.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Cloning of Trypanosoma cruzi trans-sialidase and expression in Pichia pastoris.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Differential susceptibility to acute Trypanosoma cruzi infection in BALB/c and C57BL/6 mice is not associated with a distinct parasite load but cytokine abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Vaccine adjuvants: putting innate immunity to work

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

The flagellar fraction of Trypanosoma cruzi depleted of an immunosuppressive antigen enhances protection to infection and elicits spontaneous T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

New horizons in adjuvants for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

IFN-γ plays a unique role in protection against low virulent Trypanosoma cruzi strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Functional IL‐10 Gene Polymorphism Is Associated with Chagas Disease Cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Trans-sialidase from Trypanosoma cruzi enhances the adhesion properties and fibronectin-driven migration of thymocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

ISCOM based vaccines for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

CD8+ T cells in Trypanosoma cruzi infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

The role of Toll-like receptors and adaptive immunity in the development of protective or pathological immune response triggered by the Trypanosoma cruzi protozoan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Trypanosoma cruzi: parasite persistence in tissues in chronic chagasic Brazilian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044

A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.044